← Back to search
VIVALDI BIOSCIENCES INC.
FORT COLLINS, CO, 80523
UnclaimedClaim this profile (free)
Subcontracting experience
1 record from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | OPTION 11A (0258-A468-4609)
GENERATION OF GMP REAGENT DELTAFLU H5/1
THE PURPOSE OF THIS OPTION IS TO GENERATE A NEEDED REAGENT TO CONDUCT A UNIVERSAL INFLUENZA VIRUS VACCINE CLINICAL TRIAL SPONSORED BY THE CIVIC PROGRAM. THE SPECIFIC REAGENT CONSISTS OF A GMP MANUFACTURED FINAL DRUG PRODUCT (FDP) AND THE ASSOCIATED QC INFORMATION OF THE LIVE ATTENUATED VIRUS VACCINE DELTAFLUH5/1. THIS LIVE ATTENUATED VIRUS VACCINE CONSISTS OF AN INFLUENZA A VIRUS DELETED FOR THE NS1 GENE AND CONTAINING A CHIMERIC HEMAGGLUTININ (HA) WITH THE HEAD OF AN H5 VIRUS AND THE STALK OF AN H1 VIRUS. THIS REAGENT WILL BE USED IN A CIVIC SPONSORED CLINICAL TRIAL TOGETHER WITH A GMP MANUFACTURED FDP OF THE LIVE ATTENUATED VIRUS VACCINE DELTAFLUH12/1 VIRUS, THAT WILL BE GENERATED UNDER AN ADDITIONAL OPTION 11. THE FOLLOWING SPECIFIC AIMS ARE PROPOSED:
AIM 1: PERFORM GMP PRODUCTION AND FILLING OF THE DELTAFLUH5/1 FDP FROM A BULK DRUG SUBSTANCE (BDS) STARTING MATERIAL GENERATED UNDER GRANT R01AI141226.
AIM 2: PERFORM QC TESTS OF THE DELTAFLUH5/1 FDP.
OPTION 11B (0258-A469-4609)
GENERATION OF GMP REAGENT DELTAFLU H12/1
THE PURPOSE OF THIS OPTION IS TO GENERATE A NEEDED REAGENT TO CONDUCT A UNIVERSAL INFLUENZA VIRUS VACCINE CLINICAL TRIAL SPONSORED BY THE CIVIC PROGRAM. THE SPECIFIC REAGENT CONSISTS OF A GMP MANUFACTURED FINAL DRUG PRODUCT (FDP) AND THE ASSOCIATED QC INFORMATION OF THE LIVE ATTENUATED VIRUS VACCINE DELTAFLUH12/1. THIS LIVE ATTENUATED VIRUS VACCINE CONSISTS OF AN INFLUENZA A VIRUS DELETED FOR THE NS1 GENE AND CONTAINING A CHIMERIC HEMAGGLUTININ (HA) WITH THE HEAD OF AN H12 VIRUS AND THE STALK OF AN H1 VIRUS. THIS REAGENT WILL BE USED IN A CIVIC SPONSORED CLINICAL TRIAL TOGETHER WITH A GMP MANUFACTURED FDP OF THE LIVE ATTENUATED VIRUS VACCINE DELTAFLUH5/1 VIRUS, THAT WILL BE GENERATED UNDER AN ADDITIONAL OPTION 11. THE FOLLOWING SPECIFIC AIMS ARE PROPOSED:
AIM 1: PERFORM GMP PRODUCTION AND FILLING OF THE DELTAFLUH12/1 FDP FROM A BULK DRUG SUBSTANCE (BDS) STARTING MATERIAL GENERATED UNDER GRANT R01AI141226.
AIM 2: PERFORM QC TESTS OF THE DELTAFLUH12/1 FDP. 0258-A468-4609 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: NY Parent award description: THIS CONTRACT WILL SUPPORT COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES, BASED ON PRINCIPLES OF INFLUENZA IMMUNITY, THAT ACHIEVE DURABLE, ROBUST View parent award on USAspending | — | $1,972,172 | Nov 16, 2023 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.